News
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, ...
Mini meals with bite size portions are meant to appeal to people taking GLP-1 weight-loss drugs that reduce appetite.
Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.
Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...
21h
Oprah Daily on MSNCan Combining GLP-1s and Hormone Therapy Boost Weight Loss? A New Study Shows Significant ResultsMenopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...
The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru cofounded Verve Therapeutics, a company developing a therapy that uses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results